ZymoGenetics' recent deal with Bayer HealthCare to market its new blood-clotting agent rThrombin has hit a snag. The company says that the FDA is considering its request for more manufacturing information as a major amendment to the application, which will push back final approval for the therapy. The FDA review now won't be completed until mid-January, three months later than anticipated. That marketing pact is worth up to $198 million and none of the $40 million in milestones outlined in the deal can now flow this year.
- read the report from The Street